Aviado · Research
Longevity Daily
Sunday, August 2, 2026
Listen
Today's Brief
Today's issue puts some of longevity science's firmest assumptions to the test. Our lead story brings genuine reason for optimism: a FINGERS-style dementia prevention trial is delivering real results, and researchers are openly celebrating. An old malaria drug is upending autophagy orthodoxy by extending rat lifespan 10% — not by boosting cellular recycling, but by blocking it — while a review of 350+ studies challenges the protein-maximization approach popular among biohackers. Bryan Johnson's admission that his multimillion-dollar Blueprint may have triggered autoimmune disease is a timely reminder that aggressive optimization carries its own risks.
10 stories1 trials1 Aviado original
Cognitive Health & Neuroprotection
Dementia Prevention Trial Delivers Real Results — and Scientists Are Celebrating
A large-scale FINGERS-style trial combining diet, exercise, cognitive training, and cardiovascular risk management has shown meaningful reductions in dementia risk, triggering unusual public optimism from researchers who study a disease long treated as largely inevitable. Lead investigator Miia Kivipelto and colleagues are now pointing to new blood-based biomarkers as a way to dramatically shorten future trial timelines — meaning high-quality prevention evidence could arrive in years, not decades. Nearly half of all global dementia cases may be preventable or delayable, the piece notes, citing converging evidence from multiple trial programs. If you're in your 40s or 50s and haven't started a structured prevention routine, the research window for meaningful action is open right now.
Read more →Dysfunctional Mitochondria Found to Drive Chronic Inflammation in Aging Cells
Researchers have uncovered a previously unknown metabolic signaling mechanism by which aging cells with dysfunctional mitochondria actively drive the chronic low-grade inflammation — known as inflammaging — that underpins nearly every major age-related disease. The finding points to a new class of potential targets: quieting the inflammatory signal at its mitochondrial source, rather than suppressing the immune system downstream. For readers tracking the inflammation and mitochondrial health space, this is a meaningful mechanistic advance worth following.
Read more →Supplements & Compounds
Spermidine Is Having a Moment — But Does the Anti-Aging Hype Match the Evidence?
Spermidine, found naturally in aged cheese, mushrooms, and wheat germ, has attracted a devoted following in longevity circles — with celebrity devotees like Carol Vorderman crediting daily supplementation for slowing aging, and social media users claiming dramatic weight-loss results. The compound is thought to work by stimulating autophagy, the cellular self-cleaning process that declines with age, and has been available as an OTC supplement for roughly a decade at under £1.20 per daily dose. Human evidence remains largely observational — extraordinary claims like nine stone of weight loss in under a year deserve real skepticism until controlled trials back them up.
Read more →Fatty15 Promises to Fight Aging at the Cellular Level — Here's What It's Actually Like to Take It
Fatty15, the supplement form of C15:0 (pentadecanoic acid), is generating genuine scientific interest as a compound that may protect cellular membranes and support mitochondrial function — two processes central to how cells degrade with age. Unlike most supplement coverage, this piece pairs the underlying science with a firsthand account of real-world use. Early-stage research is promising, but C15:0 hasn't yet completed the scale of human trials needed to make firm longevity claims.
Read more →Neuriva Is One of America's Best-Selling Brain Supplements. Does It Actually Work?
Pharmacy Times examines Neuriva, one of the most heavily marketed cognitive supplements in the US — endorsed by actress and neuroscientist Mayim Bialik and available in multiple formulations across major retail chains. The verdict: Neuriva's manufacturer claims support for five cognitive functions including memory and focus, but these claims have not been evaluated by the FDA, and the published evidence base for its key ingredients is thin. If you're paying premium prices for a brain supplement, this independent review is worth reading before your next reorder.
Read more →Research & Papers
An Old Malaria Drug Extends Rat Lifespan 10% — By Blocking Autophagy, Not Boosting It
The longevity world has long treated autophagy — cellular self-recycling — as an unambiguous good, with fasting protocols and supplements designed to maximize it. But a striking new study found that an old antimalarial compound extended median rat lifespan by roughly 10% by doing the opposite, inhibiting autophagy while simultaneously trimming LDL cholesterol, remodeling the IGF/growth-hormone axis, and keeping body temperature stable well into old age. This is a rat study, so direct human applications remain distant — but if the finding holds, it should give serious pause to anyone treating autophagy as a longevity dial to simply crank higher.
Read more →The Protein Paradox: A Review of 350+ Studies Suggests Less May Be More for Longevity
Americans are consuming more protein than ever, and older adults are routinely advised to eat even more to preserve muscle mass — but a sweeping review of more than 350 papers by University of Wisconsin researchers finds that protein restriction may consistently improve health outcomes and extend lifespan through mechanisms including mTOR suppression and improved metabolic signaling. The tension between muscle preservation and longevity signaling is real and unresolved, but this review suggests many optimization-oriented eaters may be inadvertently keeping aging pathways switched on. Worth reading if you've defaulted to 'more protein = better' as a health principle.
Read more →Aviado Research: New In-Depth Analysis on Longevity Science
Aviado Research's latest review-format analysis dives into the current evidence base in longevity science, synthesizing research findings to help readers separate signal from noise. The full analysis is available at the link below — a curated deep-dive for readers who want to move beyond the headlines.
Read the full Aviado analysis →Lifestyle & Nutrition
Bryan Johnson Admits Project Blueprint May Have Gone Too Far — and Doctors Agree
Bryan Johnson — who spent an estimated $2 million per year on the world's most aggressive longevity protocol — has publicly acknowledged that his Project Blueprint regimen may have pushed his body past its limits, after reportedly developing autoimmune gastritis. Physicians quoted in the piece caution that extreme intervention routines can backfire, triggering the body's stress response rather than the repair cascades biohackers intend. It's a cautionary story for anyone treating optimization as a competition: biomarkers improving on paper don't always mean the body is actually thriving.
Read more →Industry & Policy
FDA Grants Second Regulatory Acceptance to Loyal's Canine Longevity Drug
Biotech startup Loyal has received FDA regulatory acceptance for a second drug aimed at extending healthy lifespan in dogs — a notable milestone in a field where no formal regulatory pathway yet exists for human longevity therapies. Dog trials are increasingly viewed as a viable proving ground for aging interventions: dogs share our environments, develop similar diseases, and have trial timelines that don't stretch across decades. Each FDA acceptance signals growing regulatory comfort with longevity as a legitimate therapeutic category — and that normalization matters for anyone hoping to see human anti-aging drugs reach the pharmacy.
Read more →